Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1067)	7/15/1998 4:14:00 PM
From: David Cathcart	Respond to of 1826

Rick, Concerning the "observed additional evidence of antitumor activity in some patients," I suggest you call the company and talk to Dr. John MacDonald, head of R & D. A few of your minutes with him would likely equate to several hours of kicking this around on the thread. I liked what I heard on the conference call, but someone of your knowledge and background would be better served in dialogue with the source. Thanks. David

To: scaram(o)uche who wrote (1067)	7/15/1998 4:45:00 PM
From: seminole	Read Replies (1) \| Respond to of 1826

Richard <<<And here we are upon vacation time again. A year goes by so fast!>>> Maybe those Euro's are always on vacation. As I past the time waiting for a deal, I have started lifting dumbbells. I figure that at least my arms will be bigger even though my wallet is not as large as I hoped. looking for one of those Euro jobs richard

To: scaram(o)uche who wrote (1067)	7/16/1998 1:23:00 PM
From: lrb	Read Replies (1) \| Respond to of 1826

>> You mean the entire $500K? << A bit sarcastic, are we? I'd like to concentrate on Salagen for a bit. They launched for Sjogren's in April, so they had essentially a full quarter's sales effort. The product was already on the shelves, so there was no manufacturing ramp-up or channel to fill. They said in May that "the acceptance of using Salagen(R) Tablets as a treatment for the symptoms of dry mouth in Sjogren's syndrome patients has been excellent." Do you consider the $500K less than excellent? MGI believes 50,000 Sjogren's patients could benefit from Salagen. I don't recall what the product costs; how many patients does $500K represent? I had the idea that the Sjogren's market was so much larger than head&neck, and the need filled by Salagen for these patients so pressing, that we would see a much larger jump in Salagen sales. So is this just my inexperience showing, or is there cause for concern that the Sjogren's sales may not ultimately be what we had hoped for? I don't know how much of this was addressed in the conference call, because the Q&A portion of the recording is so full of drop-outs as to be unintelligible. Thanks in advance for any responses.